Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
NCT ID: NCT00088192
Last Updated: 2005-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
INTERVENTIONAL
2004-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pegaptanib sodium
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subfoveal choroidal neovascularization, secondary to age related macular degeneration, with a total lesion size \[including blood, scar/atrophy \& neovascularization\] of \< 12 total disc areas, of which at least 50% must be active CNV.
* Any subretinal hemorrhage must comprise no more than 50% of total lesion size.
General Criteria:
* Patients of either gender, aged greater than 50 years.
* Women must be using two forms of effective contraception, or be post-menopausal for at least 12 months prior to study entry, or surgically sterile. If of child-bearing potential, a serum pregnancy test must be performed within 48 hours prior to treatment and the result made available prior to treatment initiation. The two forms of effective contraception must be implemented during the study and for at least 60 days following the last dose of test medication.
* Written informed consent.
Exclusion Criteria
* Patients who are eligible for PDT with Visudyne
* Patients who are eligible for any other of the Sponsor's ongoing AMD studies still open to enrollment.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Eyetech Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Doheny Eye Institute
Los Angeles, California, United States
Connecticut Retina Consultants, L.L.C.
Bridgeport, Connecticut, United States
New England Retina Associates
Hamden, Connecticut, United States
Retina Health Center
Fort Myers, Florida, United States
Retina Associates
New Orleans, Louisiana, United States
Cumberland Valley Retina Center
Hagerstown, Maryland, United States
New England Eye Center
Boston, Massachusetts, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Associated Retinal Consultants
Royal Oak, Michigan, United States
Eye Foundation of Kansas City
Kansas City, Missouri, United States
The Eye Center of Concord
Concord, New Hampshire, United States
Vitreo- Retinal Assoc. of NJ
Belleville, New Jersey, United States
Retina Associates of New Jersey, P.A.
Teaneck, New Jersey, United States
L.I. Vitreo-Retinal Consultants
Great Neck, New York, United States
Retina Associates of Cleveland Inc.
Lakewood, Ohio, United States
Dean A. McGee Eye Institute
Oklahoma City, Oklahoma, United States
The Casey Eye Institute
Portland, Oregon, United States
Palmetto Retina Center
Columbia, South Carolina, United States
Valley Retina Associates, P.A.
McAllen, Texas, United States
University of Vermont College of Medicine
Burlington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsors Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EOP1010
Identifier Type: -
Identifier Source: org_study_id